ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Mantle-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
B-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Madrid, MD, ESP:

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in...

Enrolling
Chronic Lymphocytic Leukemia
B-cell Malignancies
Drug: Emavusertib
Drug: Zanubrutinib

Phase 2

Curis

Madrid, Spain and 10 other locations

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Madrid, Spain and 57 other locations

zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designe...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Sonrotoclax
Drug: Zanubrutinib

Phase 2

BeOne Medicines

Madrid, Spain and 32 other locations

patient populations.CAP-100 is expected to prevent the migration of leukemia cells to and their survival in lymphoid niches as well as to el...

Enrolling
Lymphocytic Leukemia, Chronic
SLL
Drug: CAP-100

Phase 1

Catapult Therapeutics

Madrid, Spain and 3 other locations

(also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Zanubrutinib
Drug: Venetoclax

Phase 3

BeOne Medicines

Madrid, Spain and 65 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 74 other locations

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Madrid, Madrid, Comunidad de, Spain and 107 other locations

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Madrid, Spain and 147 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

Madrid, Spain and 129 other locations

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic ...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib

Phase 2

Loxo Oncology
Loxo Oncology

Madrid, Spain and 131 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems